a few months ago, a group of us, reading reports of unusual patterns of RSV circulation in Australia (a "winter in summer" ncbi.nlm.nih.gov/pmc/articles/P…)
wondered whether the same might happen this year in the United Kingdom and Ireland 🧵1/n
the premise was simple: could we use a simple online questionnaire, collecting only non-patient identifiable information,
to better understand the geographical dynamics and clinical manifestations of RSV circulation in 2021/22?
It turns out we can 2/n
thanks to BronchSTART, a study powered by hundreds of clinicians in Emergency Departments, working as part of the PERUKI Network, we can now watch this year's RSV epidemic play out in real time 3/n
BronchSTART would not have taken off without the extraordinary enthusiasm and hard work of clinicians and researchers across the country: we have 31 sites recruiting so far (more to come), and already over 2,500 patients recruited 6/n
many of these clinicians have working outside their scheduled hours, on already busy shifts, to enter data for the study 7/n
the result is an incredibly high granularity map of bronchiolitis cases across the UK and Ireland which shows that this year's RSV epidemic is playing out in complicated and interesting ways, with much more regional heterogeneity than we have seen previously 8/n
our dashboard allows you to both visualise national and local trends
we can see that activity has peaked in some parts of England, but is still increasing in Scotland 9/n
as sites continue to add data we'll see whether this summer's peak will have eaten sufficiently into our immunity debt to impact on this winter season
or whether there is worse to come 10/n
a big shout out to Ormskirk District General Hospital, the biggest recruiter to the study so far, where their summer season has now finished 11/n
the dashboard is still in development so please contact us if you think it could be improved in any way 12/n
do reply to this thread if you are recruiting to BronchSTART
share pictures of your study team
and let us know how long it is taking you to fill in the study forms - reports so far are that it only takes 2-3 minutes 13/n
it has been a real privilege to be a (small) part of this fantastic project and see what can be achieved with enthusiasm, teamwork, and a shared sense of purpose @Damian_Roland@mdlyttle@wheezylikesund1@livvyswann 14/n
thank you in particular to @MyMicroreact for setting up the dashboard 15/n
and watch this space to see what happens over the autumn and winter END
• • •
Missing some Tweet in this thread? You can try to
force a refresh
a lot of interest in my thread describing the impact of RSV this year on infants and children in the UK
and questions about whether children are more at risk from RSV or COVID-19 (new🧵) 1/n
RSV (respiratory syncytial virus) is an RNA virus that causes upper and lower respiratory tract infections in children
our recently published review in Vaccine pubmed.ncbi.nlm.nih.gov/33895016/ gives an in-depth introduction to the epidemiology and virology 2/n
In the average year many thousands of children across the UK develop RSV infection: in 2016 there were 36,028 admissions for children <5 in England thorax.bmj.com/content/thorax…@PHardelid with around ~700 intensive care admissions 3/n
just finished nights on call, and found that a toxic triad of RSV, rhinovirus and SARS-CoV-2 is starting to stretch the Scottish hospital I work in to its limits
it's only August
what went wrong? 🧵1/n
Problem 1. We failed to contain SARS-CoV-2. 2/n
This is a Problem for 3 reasons.
Firstly, there are the (very) small number of children with serious SARS-CoV-2 infection. 3/n
in a typical year in England, there are ~36,000 admissions for bronchiolitis (mainly caused by Respiratory Syncytial Virus, RSV) in infants under the age of 1 thorax.bmj.com/content/75/3/2… 3/n
firstly: why should we vaccinate?
-to protect children, who can (rarely) develop severe disease, require hospitalisation, and (very rarely) die
-to protect vulnerable individuals who have contact with children
-to achieve herd immunity: 21% of UK population aged under 18 2/n
secondly, what do we need to vaccinate children?
-a vaccine that robustly protects against severe disease AND prevents transmission
-robust safety data, including paediatric-focused studies & post-licensure monitoring for potential rare outcomes like vaccine-associated MIS-C 3/n
to allow sporting events to take place this summer?
Israel Start-Up Nation, a cycling team, already in "close talks with the Israeli Ministry of Health to assess whether, if there are vaccines available after the main programme takes place, the team can be allocated some.” 2/4
and if athletes merit preferential treatment, should other cultural figures (actors, musicians) get preferential treatment too?
I would argue not, but interested to see what @Twitter thinks 3/4